By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...

This ends a drawn out legal battle brought by Genevant and Arbutus against Moderna under a week before the jury trial was set to begin.

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine landscape—Moderna has resolved a long-running patent feud. | Moderna will pay $950 ...

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s ...

The settlement could go as high as $2.25 billion.

Feb 19 (Reuters) - German biopharmaceutical company BioNTech sued Moderna in Delaware federal court on Thursday, alleging that Moderna's COVID-19 vaccine mNEXSPIKE infringes a patent related to ...

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used ...

Two vaccine candidates using similar technology are winning the COVID-19 vaccine race in the U.S., and in the process validating the mRNA platform — which is yet untested on the market — as well as ...

MOUNTAIN VIEW, Calif. -- It was the second shot California resident Veena Thomas had been for waiting for. Instead of relief what she felt was panic after the needle was pulled out. RELATED: Here's ...

WASHINGTON — Pfizer and Moderna say the Food and Drug Administration have opened up COVID-19 booster shots to all adults, letting them choose another dose of either vaccine. The move expands the ...

AI revolutionizes pharma manufacturing by enhancing efficiency, quality, and cost-effectiveness. Key opportunities include predictive maintenance, real-time quality control, and supply chain ...